Pharmacologic approaches to glycemic treatment. American Diabetes Association. Diabetes Care. 2017;40 (suppl 1):S64-S74.
2.
HeerspinkHJLPerkinsBAFitchettDH. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752-772.
3.
ZinmanBWannerCLachinJM. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
4.
KosiborodMCavenderMAFuAZ. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation. 2017;136(3):249-259.
5.
NealBPervokicVMahaffeyKW. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.
6.
WannerCInzucchiSELachinJM. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-334.
7.
NealBPerkovicVZeeuwDD. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38:403-411.
8.
CherneyDUdellJA.Use of sodium glucose cotransporter 2 inhibitors in the hands of cardiologists: with great power comes great responsibility. Circulation. 2016;134:1915-1917.
